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Introduction: Falls and fractures are a cause of substantial morbidity in Parkinson's. Despite 
an excess risk of both falls and osteoporosis, people with Parkinson's perceive that they are 
less likely to fracture than their peers, despite actually being at higher fracture risk. 
Recognising this increased risk, in 2014 we published an algorithm to guide management of 
fracture risk in this high-risk population. Recently, the National Osteoporosis Guideline 
Group (NOGG) published new guidance revising the 10 year fracture probability intervention 
thresholds for those over 70 years old to 20.3% for major osteoporotic fracture and 5.4% for 
hip fracture. 
Methods:  In light of the new guidance, we have reappraised the use of two fracture 
prediction tools, Qfracture and FRAX, and have updated the algorithm to guide the 
management of bone health and fracture risk in people with Parkinson's.  
Results: We outline the treatment options available with particular consideration given to 
Parkinson specific factors that influence treatment choices.  
Conclusion: This guidance is relevant to all healthcare specialist managing Parkinson’s 






Parkinson’s disease (PD), the commonest neurodegenerative disorder after Alzheimer’s 
disease, affects 145,000 adults in the UK [1]. In Parkinson’s falls are common and the 
consequent fractures account for substantial morbidity [2]. People with Parkinson’s are more 
than twice as likely to have osteoporosis compared to unaffected individuals of the same age 
[3] and twice as likely to sustain a fracture, likely resulting from the combination of increased 
fall risk and osteoporosis [4]. Despite this, awareness of fracture risk within the Parkinson’s 
population is lacking; women with Parkinson’s perceive themselves ‘as likely or less likely’ 
to fracture a bone compared with their peers [5].  This is perhaps not surprising as clinicians 
often overlook fracture risk; the 2015 UK Parkinson’s Audit highlighted widespread lack of 
bone health assessment in Parkinson’s outpatients [6].  
 
The increased fracture risk associated with Parkinson’s is particularly marked at the hip, with 
patients typically lacking the rapid protective abduction of the arms during falls [7]. Of the 
osteoporotic fractures, hip fractures have the greatest impact on functional recovery and 
mortality, with particularly adverse outcomes in Parkinson’s patients [8,9]. Hip fracture 
admissions account for 4.2% of all Parkinson’s admissions in England, with an average 
yearly cost estimated at £13.7 million [10].  
 
Men with Parkinson’s seem to be at particular risk of hip fracture. In a prospective study of 
primary care records from 3.1 million UK patients (0.2% having a diagnosis of Parkinson’s), 
Parkinson’s was associated with a 3-fold increased risk of hip fracture in men (Hazard Ratio 
3.0 [95%CI 2.4,3.8]), and a 2-fold increase in women (2.0 [1.8,2.4]) [11]. Our own analyses 
of English Hospital Episodes Statistics have shown a year-on-year increase in the absolute 
number of men with Parkinson’s sustaining a hip fracture in England, such that by 2014 
almost as many men with Parkinson’s fractured as did women with Parkinson’s (Figure 1), 
 
 
whilst the most recent meta-analysis demonstrates that patients with Parkinson’s are 4 times 
(hazard ratio 4.02 [95% CI 4.00, 4.03]) more likely to sustain a hip fracture than their peers 
([12], manuscript in review). Critically, now in the US each year 17.6% of women with 
Parkinsons’ aged 65 years or older will sustain a clinical fracture, and 4.6% will sustain a hip 
fracture; amongst men of a similar age 11.7% will sustain a clinical fracture with 2.9% 
experiencing a hip fracture ([12], manuscript in review). 
Figure 1 Total number of men and women aged 65 or older with idiopathic Parkinson’s, who sustained a hip 
fracture each year from 2001 to 2014 in England. 
 
Aims 
In 2014, we published the first algorithm to guide the assessment and management of fracture 
risk in people with Parkinson’s [13]. This original algorithm comprised 6 steps, sometimes 
requiring two different risk calculation tools.  The complexity of this approach, though 
necessary at the time to reconcile Parkinson’s-specific assessment with national guidance, 
likely contributed to sub-optimal uptake [6]. This, combined with the recent publication of 
new national guidelines by the UK-based National Osteoporosis Guideline Group 





















































widespread clinical use in the UK. This revised ‘BONE-PARK’ algorithm, which applies 
NOGG guidance specifically to Parkinson’s patients, streamlines fracture risk assessment and 
is applicable to the practice of both primary and secondary care clinicians. 
Fracture risk intervention thresholds 
In 2017 NOGG published new guidelines containing revised fracture risk intervention 
thresholds directing use of anti-osteoporosis treatments [14].  This new NOGG guidance, 
accredited by the National Institute for Health and Care Excellence (NICE), [15] 
recommends that fracture risk be assessed using the FRAX tool in all postmenopausal 
women, and in men age 50 years or older, who have risk factors for sustaining a fracture; 
Parkinson’s is now listed as such a risk factor [14].  
 
FRAX calculates a person’s probability of sustaining a hip fracture and a major osteoporotic 
fracture (MOF), over the next 10 years. NOGG then applies thresholds for intervention to the 
FRAX probability of MOF to make a recommendation that either reassurance and lifestyle 
advice be provided to the patient, or for a Dual-energy X-ray absorptiometry (DXA) to be 
performed to quantify bone mineral density (BMD), or for initiation of bone-protective 
therapy. As before, up until the age of 70 years the intervention threshold for treatment is set 
at a risk equivalent to that associated with a prior fracture, and therefore rises with age. Now 
from age 70 years, fixed thresholds are applied ensuring older patients without a history of a 
prior fracture have equitable access to treatment. The fixed intervention thresholds equate, 
after DXA scanning, to the mean probability at age 70 of sustaining a MOF (20.3%) [16]. 
This threshold of 20.3% captures approximately 92% of fracture cases over the age of 75 
[16]. The alternative intervention threshold, based on probability of hip fracture, is set as the 
mean probability at age 70, for a woman with BMI 24kg/m2 and a prior fracture, of 
sustaining a hip fracture, which is 5.4% [16]. Intervention thresholds for men and women are 
 
 
similar. Optional addition of measured BMD can then refine fracture risk prediction if 
needed, by adding femoral neck T-score into the FRAX algorithm. 
 
Application of intervention thresholds on populations with Parkinson’s 
It is notable that the NOGG recommendations are principally based upon calculated MOF 
probabilities rather than those for hip fracture alone. This is of relevance in Parkinson’s 
(particularly for men) where hip fracture risk is substantially elevated compared to other 
MOF fracture sites, potentially rendering the NOGG algorithm less applicable to men with 
Parkinson’s.   
 
The discordance between the probabilities of MOF versus hip fracture by sex and the 
potential risk of gender inequity when applying intervention thresholds in Parkinson’s is 
shown in Figure 2. These data, gathered systematically from unselected Parkinson’s patients 
assessed in routine outpatient clinics across two typical NHS hospitals, show the relative 
dominance of calculated hip fracture risks in men compared with that of MOF in women 





Figure 2.  Proportion of FRAX results above threshold for investigation or intervention, by age and sex, in 284 Parkinson’s patients from 2 typical 
outpatient cliics, [mean age 73.0 years (SD 9.4), 60% male, median BMI 26.4 (IQR 23.2 – 29.0)]  
  
2a. FRAX results without using Parkinson’s as a cause of 
secondary osteoporosis 
   
















































































































































































































Choice and application of fracture risk assessment tools in Parkinson’s  
NICE [17] has endorsed two fracture risk assessment tools for use in the UK – FRAX [18] and 
QFracture [11]. FRAX, supported by NOGG, [14] is the mostly widely used. However, each has 
limitations in the context of Parkinson’s.  
FRAX and Parkinson’s 
One caveat to FRAX utility is the absence of Parkinson’s as a specified clinical risk factor within 
the FRAX tool. However, Parkinson’s is associated with an increased risk of both osteoporosis 
and fractures, [3,4] likely for reasons of reduced mobility, low vitamin D, poor nutrition and 
medication effects [19]. This increased fracture risk seen in Parkinson’s is equivalent to, and 
arguably exceeds, many of the ‘secondary osteoporosis’ conditions listed within the FRAX tool. 
Whilst a number of secondary causes of osteoporosis are not included in FRAX, including 
Parkinson’s, FRAX authors have listed Parkinson’s as an example of immobility-induced 
secondary osteoporosis [20]. Thus it reasonable to consider Parkinsons’ pragmatically as a 
secondary cause of osteoporosis when calculating FRAX. The effect of this approach for men and 
women is illustrated in Figure 2b and demonstrated across a range of ages and BMIs in Figure 3 





Figure 3 The effect of including Parkinson’s as a secondary cause of osteoporosis on hip fracture probability for men and 
women with PD across a range of ages and BMIs 
Men                 
 
90 16.0 16.0 15.0 15.0 14.0 13.0 13.0 12.0 12.0 11.0 10.0 10.0 9.5 9.0 7.6 
85 13.0 12.0 12.0 11.0 11.0 10.0 10.0 9.6 9.2 8.8 8.4 8.0 7.6 7.2 6.0 
80 9.9 9.4 9.0 8.6 8.2 7.6 7.3 6.9 6.5 6.2 5.8 5.5 5.2 4.8 4.1 
75 7.3 6.9 6.5 6.2 5.8 5.4 5.0 4.7 4.3 4.0 3.7 3.5 3.3 3.2 2.7 
70 5.2 4.8 4.5 4.0 3.8 3.5 3.2 2.9 2.7 2.5 2.2 2.1 2.0 1.9 1.6 
65 3.6 3.3 2.9 2.7 2.4 2.2 2.0 1.8 1.6 1.5 1.3 1.3 1.2 1.1 1.0 
60 2.3 2.1 1.9 1.7 1.5 1.3 1.2 1.1 1.0 0.9 0.8 0.7 0.7 0.7 0.6 
55 1.3 1.2 1.1 1.0 0.9 0.8 0.7 0.6 0.5 0.5 0.4 0.4 0.4 0.4 0.3 
Women 
                 
 
85 30.0 29.0 28.0 27.0 25.0 24.0 23.0 22.0 20.0 19.0 18.0 17.0 16.0 15.0 13 
80 25.0 24.0 22.0 21.0 19.0 18.0 17.0 15.0 14.0 13.0 13.0 11.0 11.0 10.0 8.7 
75 18.0 17.0 15.0 14.0 13.0 12.0 11.0 9.7 8.8 8.0 7.1 6.8 6.5 6.1 5.2 
70 12.0 11.0 9.6 8.7 7.8 7.0 6.3 5.7 5.0 4.5 4.0 3.8 3.6 3.5 3.0 
65 7.1 6.4 5.7 5.1 4.5 4.0 3.6 3.2 2.8 2.5 2.2 2.1 2.0 1.9 1.7 
60 4.2 3.7 3.3 2.9 2.6 2.3 2.0 1.8 1.6 1.4 1.2 1.2 1.1 1.1 0.9 
55 2.3 2.0 1.8 1.6 1.4 1.2 1.1 1.0 0.9 0.7 0.7 0.6 0.6 0.6 0.5 
  15 16 17 18 19 20 21 22 23 24 25 26 27 28 31 
        BMI         
Probability of a Hip fracture in men and women with ‘Secondary osteoporosis’ selected as only FRAX risk factor. 
Above the solid bold line, 10-year hip fracture probability is above the threshold of 5%. The figures are not 










FRAX and falls 
Of people living with Parkinson’s, 60% fall each year, with 39% falling recurrently [21]. 
However, FRAX does not accommodate falls as a clinical risk factor and likely underestimates 
fracture probability in those who fall [22]. In 2011 a joint position statement concluded that 
clinicians should recognize that patients with frequent falls are at higher fracture risk than 
currently estimated by FRAX and consider this when decision-making [22]. Specifically, they 
recommended that FRAX reports should include the statement “Data from the Study of 
Osteoporotic Fractures suggest that in comparison to individuals without a fall in the previous 
year, a history of each fall (up to 5 falls or more) in the previous year increases the 10-year hip 
fracture risk by approximately 30% in women”. Thus, a 4% hip fracture probability in a patient 
with two recent falls would inflate to 6.2%. This assumes that the US population in the Study of 
Osteoporotic Fractures, on which this statement is based, is generalisable to the UK [23]. 
Although it may be argued that patients whose fracture risk is driven more by falls than low bone 
density might have less to gain from agents affecting bone metabolism, there is strong evidence 
that fracture risk reduction is achieved irrespective of a BMD diagnosis of osteoporosis [24].  
QFracture and Parkinson's 
QFracture, which is less widely used than FRAX, is derived from prospective primary care data 
from 3.1 million UK patients; 0.2% had a Parkinson’s diagnosis [11]. Its advantages include (i) 
inclusion of Parkinson’s and falls as independent clinical risk factors, and (ii) the ability to 
generate fracture risk estimates for annual increments up to 10 years; this flexibility aids decision 
making where life expectancy is challenged by progressive degenerative disease. However, 
QFracture, which is lengthier to complete than FRAX, cannot incorporate BMD measurement and 
furthermore, whilst independent external validation in the UK has shown QFracture predicts hip 
fracture well and comparably with FRAX, the calibration for MOF tends to over-estimate risk 
 
 
compared with FRAX, [25] which may be explained by data deficiencies in the computerised 
primary care records from which QFracture was originally derived [26]. 
 
On balance, given the widespread use of FRAX and newly revised intervention thresholds from 
NOGG, FRAX seems a better tool to use in the context of Parkinson’s. However, in certain 
circumstances QFracture may be better suited to calculate hip fracture risk, for example in those 
with multiple comorbidities including falls, and in individuals with short life expectancies such as 
is seen in Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA), where 
calculation of fracture risk over a shorter timeframe (e.g. <5 years) may be helpful.  
 
In light of the new NOGG guidance, we introduce here a revised algorithm BONE-PARK (Figure 
4), to guide assessment and management of fracture risk, in Parkinson’s. This algorithm should be 
considered within the context of a multifactorial assessment of fall risk factors.  Clinicians should 
consider additional factors alongside bone health that are amenable to intervention such as 
medication review [27], physiotherapy intervention [28], exercise [29]  and environmental 
modification.   
 
 




Step 1: Optimise calcium and vitamin D intake and lifestyle factors 
There is a high prevalence of vitamin D deficiency in people with Parkinson’s with 91% of those 
insufficient and 67% deficient (at mean Hoehn and Yahr stage 2, average age 66 years) [30]. 
Recurrent falls amongst Parkinson’s patients supports consideration of testing [21,31]. Vitamin D 
deficiency and insufficiency should prompt vitamin D replacement, then maintenance, with or 
without calcium supplementation according to dietary calcium intake [31]. Interestingly the 
Scientific Advisory Committee on Nutrition (SACN) recommends daily supplementation in all 
those aged ≥65 years with inadequate sun exposure [32]. 
Step 2: Assess prior falls and fractures 
All patients should be routinely asked about the occurrence of falls, near falls and any previous 
fractures with referral to multi-disciplinary falls services as needed. A history of height loss, acute 
back pain or kyphosis disproportionate to their neuromuscular condition, should prompt 
investigation with lateral thoraco-lumbar radiographs to identify occult morphometric vertebral 
fractures; of note the majority of vertebral fractures fail to present to medical attention 
[33].  Incidental findings of vertebral fracture on radiological investigations performed for other 
indications must not be disregarded but reported and included as a prior fracture when assessing 
future risk [34].  BONE-PARK must be applied in conjunction with a comprehensive falls 
prevention strategy that tackles both generic and Parkinson’s-specific risk factors [27].   
Step 3: Calculate the 10-year probability of hip and MOF using the FRAX tool  
The presence of Parkinson’s should be considered as a secondary cause of osteoporosis when 
calculating FRAX. Using UK FRAX permits direct linkage to NOGG guidance. 
Step 4: Use the NOGG intervention guidance 
If the MOF probability warrants treatment, follow the guidance given, and in relatively fit or 
younger patients aged ≤70 years, consider baseline BMD measurement by DXA for future 




If BMD measurement is recommended a DXA scan should be requested where feasible and 
appropriate (see below). Where DXA is impractical, we propose empirical anti-osteoporosis 
treatment if the hip fracture probability is ≥5% in men, and in women if the probabilities of MOF 
are ≥20% and for hip fracture ≥5%.  
 
If NOGG guidance suggests that lifestyle advice only is warranted, this should be considered with 
the caveat that falling patients with a MOF probability close to the BMD measurement threshold 
may be considered for DXA where feasible, or if not feasible, for treatment as per the intervention 
thresholds given above. Patients fulfilling the criteria for treatment by NOGG and the BONE-
PARK algorithm should be considered for anti-osteoporosis medication, as well as falls 
intervention and lifestyle advice.  
BMD measurement considerations 
A DXA scan can refine the FRAX fracture risk prediction and/or provide a baseline BMD for 
future comparison in, for example, 3-5 years’ time. Hence DXA should be considered in those at 
an early enough stage of their movement disorder where re-testing of BMD is expected to be 
possible. BMD quantification by DXA should prompt recalculation of FRAX probabilities. Anti-
osteoporosis treatment should be reviewed after 5 years (3 years if treating with annual Zoledronic 
Acid infusions) and continued in cases of prior hip or vertebral fracture, recurrent fractures, 
current glucocorticoid treatment, or in those aged >75 years, although in the case of recurrent 
fracture the type of anti-osteoporosis treatment may need to change [14].    
 
Access to DXA may be restricted by local resource or patient ability as testing necessitates 
climbing onto a fixed height unpadded table, lying supine and maintaining this position for 
approximately ten minutes. Though BMD measurement can refine fracture risk calculations and 
 
 
guide treatment, barriers to obtaining BMD should not preclude empirical anti-osteoporosis 
treatment where appropriate. 
Special populations and circumstances 
In those with limited life expectancy, multiple comorbidities or where quantification of fracture 
probability over a shorter time (<5 years) period is desired, QFracture can be used and a treatment 
threshold of ≥5% for hip fracture applied.  This may have particular utility for those assessed in a 
more complex phase of their Parkinson’s, or with a more rapidly progressive movement disorder.  
Scope of the BONE-PARK algorithm 
Given the increase in fracture risk, seen even in early Parkinson’s,[8] and the time taken to gain 
treatment benefit with anti-osteoporosis medications (>12 months), this BONE-PARK algorithm 
is appropriate for use in the majority of patients, from Hoehn and Yahr stages 1-4 and in patients 
with Parkinsonian disorders with high falls risk such as PSP and Dementia with Lewy Bodies. In 
the later stages of life, the transition to a more palliative management approach should prompt re-
evaluation of treatment interventions balanced against, what is often by then, very high fall and 
fracture risks. 
Assessment schedule and treatment review  
In Parkinson’s, bone health should be reviewed annually, including assessment of treatment 
adherence (including calcium and vitamin D). Poor adherence to oral bisphosphonates is common 
and associated with higher fracture rates; [35] treatment is frequently discontinued due to 
intolerance, insufficient motivation or concern over potential side effects [36]. This should prompt 
consideration of parenteral anti-osteoporosis treatment options. BONE-PARK is designed to help 
guide clinical decision making but individual treatment strategies should be determined in 
discussion with the patient, together weighing the potential burden of additional medication 
versus the benefit of fracture risk reduction.   
 
 
Treatment options  
NOGG provides guidance on anti-osteoporosis treatment options; these are included within 
BONE-PARK, adapted for Parkinson’s.   
 
All patients should be counselled to avoid smoking, increase physical activity levels and limit 
alcohol intake. Adequate vitamin D maintenance should be instigated in all those aged >65 years 
with inadequate sunlight exposure; SACN recommends a minimum dose of 800 IU 
cholecalciferol for postmenopausal women and for men >50 years at risk of fracture [31]. It is 
standard practice to recommend a combined calcium and vitamin D preparation to older patients. 
In those who feel their diet is replete in calcium, a calcium calculator can quantify intake and can 
support a decision to supplement vitamin D alone [37].  
 
Oral bisphosphonates, particularly alendronic acid (70mg weekly), are first-line pharmacological 
treatments for osteoporosis with high quality evidence for important fracture risk reductions after 
three years of treatment [14]. Oral bisphosphonates have little difference in tolerability; however, 
risedronate (35mg weekly) is licenced for use at a slightly lower eGFR of 30 ml/min (vs. 35 
ml/min for alendronic acid) [38]. Evidence specific to patients with Parkinson’s is lacking, but 
efficacy is likely to be as good and absolute risk reductions likely greater in this high risk 
population. However, the dosing schedule for oral bisphosphonates includes a strict early-morning 
fasting regime, ideally prior to other tablet taking, with a full glass of water, maintaining an 
upright position with further fast for ≥30 minutes post-dose. Problematic dysphagia, compromised 
posture, cognitive impairment, poor gastrointestinal motility and/or already complex drug 
regimens may often limit utility of oral anti-resorptive agents in those with Parkinson’s. Monthly 
ibandronate can be considered; however, its evidence-base is mainly limited to vertebral fracture 
reduction [14,39]. Swallow issues may be ameliorated by the use of liquid alendronic acid but 
 
 
non-inferiority trial data are scant. Hence, intravenous zoledronic acid, usually given yearly for 3 
years, represents an attractive and affordable option, [40] with substantial fracture risk reductions 
achieved by 3 years (40% non-vertebral and 75% vertebral fracture relative risk reduction) [41]. 
Interestingly, a single, one-off infusion appears to yield 5 years of reduced bone turnover with 
sustained gains in BMD and therefore has particular appeal in those patients less able to attend 
yearly clinics for infusions [42]. However, it is notable that there have been no trials in a 
Parkinson’s population of single-dose  Zoledronic acid with BMD or fracture 
outcomes. Zoledronic acid is highly efficacious even in those without DXA defined osteoporosis 
(defined by BMD T-score <-2.5), and equally efficacious irrespective of prior fracture history 
[43].   Zoledronic acid has also been shown to reduce the risk of death, myocardial infarction and 
cancer suggesting that there are systemic benefits beyond fracture reduction [43,44].   
 
Denosumab, a human monoclonal antibody to Receptor activator of nuclear factor kappa-Β ligand 
(RANKL), given subcutaneously on a six-monthly basis, is a further parenteral anti-resorptive 
treatment option. It lacks the renal restrictions of the bisphosphonates, and trials included 
participants with eGFR as low as 15 ml/min [45]. The risk of secondary hypocalcaemia is 
increased in poorer renal function and concerns have been raised when stopping denosumab, due 
to rebound increases in bone turnover which may be associated with a paradoxical  increased risk 
of vertebral fracture [46]. Therefore the advice is not to stop denosumab treatment without first 
considering alternative treatments to ameliorate the transient period of high bone turnover [46].  
However, bearing these points in mind, both zoledronic acid and denosumab, which convey 





Other treatment options include raloxifene and oestrogen replacement in women, and 
subcutaneous teriparatide although its high cost severely restricts its use to those at very high risk 
of vertebral fractures [47]. 
Conclusion 
This revised BONE-PARK algorithm, underpinned by FRAX and informed by the newly updated 
NOGG guidance, is a simple guide for Parkinson’s clinicians. A small subset of patients with 
complex comorbidities and/or short life expectancy may benefit from QFracture assessment of hip 
fracture risk. BONE-PARK can be applied whether or not BMD measurement is available and 
includes recommendations for the frequency of reviews of both fracture risk and treatment.   
 
The accurate and timely assessment of fracture risk in Parkinson’s remains a challenge to 
clinicians.  Multiple motor and non-motor symptoms compete for attention during review, patients 
are unlikely to raise fracture risk as an issue, and movement disorder specialists may be less 
familiar with fracture risk assessment and management. However, the chronicity of the condition 
of Parkinson’s gives ample opportunities to reduce the risk of falls and consequent fractures by 
timely assessment and intervention. We propose BONE-PARK is routinely adopted into non-
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Supplementary data 1.  The effect of including Parkinson’s as a secondary cause of osteoporosis on major osteoporotic fracture 
probability for men (A) and women (B) with PD across a range of ages and BMIs 
A. Probability of a Major Osteoporotic Fracture: MEN with ‘Secondary osteoporosis’ selected as only FRAX risk factor 
                 
 90 18.0 18.0 17.0 17.0 17.0 16.0 16.0 15.0 15.0 15.0 15.0 14.0 13.0 13.0 11.0 
Age 
85 15.0 14.0 14.0 14.0 14.0 14.0 13.0 13.0 13.0 13.0 13.0 12.0 12.0 11.0 10.0 
80 12.0 12.0 12.0 12.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 10.0 9.8 9.3 8.3 
75 10.0 10.0 9.9 9.8 9.6 9.4 9.3 9.2 9.0 8.9 8.8 8.5 8.2 7.9 7.0 
70 9.0 8.8 8.7 8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.9 7.6 7.4 7.1 6.4 
65 7.6 7.5 7.3 7.2 7.1 7.0 6.9 6.9 6.8 6.7 6.7 6.5 6.3 6.0 5.6 
60 6.0 5.9 5.8 5.7 5.6 5.5 5.4 5.4 5.3 5.3 5.3 5.1 5.0 4.8 4.4 
55 4.9 4.8 4.7 4.7 4.6 4.6 4.5 4.5 4.5 4.4 4.4 4.3 4.2 4.1 3.7 
  15 16 17 18 19 20 21 22 23 24 25 26 27 28 31 
        BMI         
Above the solid bold line, 10-year MOF fracture probability is above the threshold of 20%  
B. Probability of a Major Osteoporotic Fracture: WOMEN with ‘Secondary osteoporosis’ selected as only FRAX risk factor 
                 
Age  
85 36.0 35.0 35.0 34.0 34.0 33.0 33.0 32.0 32.0 31.0 31.0 30.0 29.0 28.0 25 
80 32.0 31.0 30.0 29.0 28.0 28.0 27.0 26.0 26.0 25 25.0 24.0 23.0 22.0 20 
75 26.0 25.0 24.0 23.0 22.0 22.0 21.0 20.0 20.0 19.0 19.0 18.0 18.0 17.0 15 
70 21.0 20.0 19.0 18.0 18.0 17.0 17.0 16.0 16.0 15.0 15.0 15.0 14.0 14.0 13 
65 15.0 15.0 14.0 14.0 13.0 13.0 13.0 12.0 12.0 12.0 12.0 11.0 11.0 11.0 9.7 
60 10.0 10.0 9.7 9.4 9.2 8.9 8.7 8.5 8.4 8.2 8.1 7.9 7.7 7.4 6.8 
55 7.5 7.3 7.1 6.9 6.7 6.6 6.5 6.4 6.3 6.2 6.1 6.0 5.8 5.6 5.2 
  15 16 17 18 19 20 21 22 23 24 25 26 27 28 31 
        BMI  
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